key: cord-0741303-0u75n5db
authors: Li, Sijia; Hu, Zhigang; Song, Xinyu
title: High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19
date: 2020-06-26
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa829
sha: a37b6157d4c3c0b4c22b866d6a8af6b8939aee9e
doc_id: 741303
cord_uid: 0u75n5db

nan

days) is recommended as adjuvant therapy of COVID-19 in China [1] . We read with interest the recent study by Xu et al [2] who determined risk factor associated with prolonged viral shedding in patients with COVID-19. They reported that use of corticosteroids was associated with higher probability of late viral RNA clearance (≥15 days after illness onset) in unvariate logistic regression analysis (P = 0.025), but not shown in multivariate logistic regression analysis (OR= 1.38, 95%CI: 0.53, 3.65, P = 0.519).

Systemic corticosteroids always was controversy in treating viral pneumonia. A newly published meta-analysis demonstrated that corticosteroids treatment was associated with longer length of stay, higher probability of bacterial infection and mortality among patients with coronavirus pneumonia [3] . In addition, whether systemic corticosteroids delay viral clearance is another topic priority. The first randomized controlled trial about corticosteroids and viral clearance observed that patients with early use of hydrocortisone harbored higher plasma SARS-CoV viral load and longer time of viral shedding than those without hydrocortisone [4] . During no use of corticosteroids [5] . High-dose corticosteroids seemingly were more likely to prolong viral clearance of MERS. Ogimi and the colleagues [6] further suggested that high-dose steroids (> 1 mg/kg) were associated with prolonged shedding of human coronavirus than low-dose steroids (≤ 1 mg/kg). Actually, a dose-response manner about corticosteroid and viral shedding also was shown in influenza viral pneumonia. Two studies from Cao et al [7] and Boudreault et al [8] also observed that prolonged shedding of influenza viral was found in high-dose corticosteroids, but not shown in low-dose corticosteroids.

We collected more than 60 variables from 206 patients with COVID-19 to assess 

National Health Commission of the People's Republic of China. The notice of launching guideline on diagnosis and treatment of the novel coronavirus pneumonia (NCP)

Factors associated with prolonged viral RNA shedding in patients with COVID-19

The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

Prolonged Shedding of Human Coronavirus in Hematopoietic Cell Transplant Recipients: Risk Factors and Viral Genome Evolution

Adjuvant corticosteroid treatment in adults with inflfluenza A (H7N9) viral pneumonia

Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus

Prescription-drug-related risk in driving: comparing conventional and lasso shrinkage logistic regressions

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan